초록접수 현황
| 21F-106 | 구연 발표 |
Comparative Analysis of Long Term Result between Single Incision VATS and Multi-port VATS; Can Single Incision VATS be an Alternative to Multi-port VATS in Lung cancer surgery?
Joo Hyung Son, Do Hyung Kim
Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Seoul, Republic of Korea
Purpose : Even though many reports were proposed that single incision VATS (SITS ) is superior to multi-port VATS (MVATS) in clinical stage I non-small cell lung cancer (NSCLC), SITS could not gain general consent as alternative of conventional VATS because there are no report about long term results .
Methods : From March 2011 to December 2015, 217 patients who were diagnosed with clinical stage I NSCLC underwent anatomical resection. Of these, 98 underwent MVATS and 119 underwent SITS. The median follow-up time was 69.0±24.8 months (range, 2-88 months). The survivor was observed for at least five years.We retrospectively reviewed and compared to the early postoperative and long term results between SITS and MVATS.
Results : There were no significant differences between SITS and MVATS with regard to conversion rate, number of lymph node, complications, in-hospital mortality. SITS had longer operating time than MVATS. Chest tube drainage for 24 hours after operation and intraoperative blood loss are superior with SITS. The 5-year disease-free survival (DFS) rate was 79.8% in MVATS and 86.0% in SITS for clinical stage I NSCLC (p = 0.441)(Fig 1a). The 5-year overall survival (OS) rate was 77.6% in MVATS and 79.0% in SITS group for clinical stage I NSCLC (p = 0.477)(Fig 1b). There was no difference in long-term survival between the two groups.
Conclusion : SITS for non-small cell lung cancer could achieve a little benefit of short-term surgical results comparing MVATS, but we could not find oncological superiority of SITS from the perspective of long term survival. SITS would be better to consider another option than an alternative for MVAT .
Methods : From March 2011 to December 2015, 217 patients who were diagnosed with clinical stage I NSCLC underwent anatomical resection. Of these, 98 underwent MVATS and 119 underwent SITS. The median follow-up time was 69.0±24.8 months (range, 2-88 months). The survivor was observed for at least five years.We retrospectively reviewed and compared to the early postoperative and long term results between SITS and MVATS.
Results : There were no significant differences between SITS and MVATS with regard to conversion rate, number of lymph node, complications, in-hospital mortality. SITS had longer operating time than MVATS. Chest tube drainage for 24 hours after operation and intraoperative blood loss are superior with SITS. The 5-year disease-free survival (DFS) rate was 79.8% in MVATS and 86.0% in SITS for clinical stage I NSCLC (p = 0.441)(Fig 1a). The 5-year overall survival (OS) rate was 77.6% in MVATS and 79.0% in SITS group for clinical stage I NSCLC (p = 0.477)(Fig 1b). There was no difference in long-term survival between the two groups.
Conclusion : SITS for non-small cell lung cancer could achieve a little benefit of short-term surgical results comparing MVATS, but we could not find oncological superiority of SITS from the perspective of long term survival. SITS would be better to consider another option than an alternative for MVAT .
책임저자: Do Hyung Kim
Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Seoul, Republic of Korea
발표자: Joo Hyung Son, E-mail : pnumed09@naver.com